8 min
The why, when, where, how, and so what of so-called rapidly acting antidepressants NPP BrainPod
-
- Sciences
Sanjay Mathew is a professor and vice chair for research at Baylor College of Medicine and director of the Mood and Anxiety Disorders Program. He’s one of the two authors of a recent review paper in the journal Neuropsychopharmacology, “The why, when, where, how, and so what of so-called rapidly acting antidepressants.”
With his colleague Alan Schatzberg, professor of psychiatry and behavioral sciences and director of the Mood Disorders Center at Stanford University, they explore both the drugs that have been studied as rapidly-acting anti-depressants to date, and they also review the challenges and opportunities in how such research is conducted. They say that a version of ketamine has changed the field.
Read the full study here: https://www.nature.com/articles/s41386-023-01647-8
Hosted on Acast. See acast.com/privacy for more information.
Sanjay Mathew is a professor and vice chair for research at Baylor College of Medicine and director of the Mood and Anxiety Disorders Program. He’s one of the two authors of a recent review paper in the journal Neuropsychopharmacology, “The why, when, where, how, and so what of so-called rapidly acting antidepressants.”
With his colleague Alan Schatzberg, professor of psychiatry and behavioral sciences and director of the Mood Disorders Center at Stanford University, they explore both the drugs that have been studied as rapidly-acting anti-depressants to date, and they also review the challenges and opportunities in how such research is conducted. They say that a version of ketamine has changed the field.
Read the full study here: https://www.nature.com/articles/s41386-023-01647-8
Hosted on Acast. See acast.com/privacy for more information.
8 min